Applied Health Economics and Health Policy

, Volume 13, Issue 2, pp 149–156 | Cite as

A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States

  • Ya-Lin A. HuangEmail author
  • Arielle Lasry
  • Angela B. Hutchinson
  • Stephanie L. Sansom
Systematic Review



The Centers for Disease Control and Prevention (CDC) focus on funding HIV prevention interventions likely to have high impact on the HIV epidemic. In its most recent funding announcement to state and local health department grantees, CDC required that health departments allocate the majority of funds to four HIV prevention interventions: HIV testing, prevention with HIV-positives and their partners, condom distribution and policy initiatives.


We conducted a systematic review of the published literature to determine the extent of the cost-effectiveness evidence for each of those interventions.


We searched for US-based studies published through October 2012. The studies that qualified for inclusion contained original analyses that reported costs per quality-adjusted life-year saved, life-year saved, HIV infection averted, or new HIV diagnosis. For each study, paired reviewers performed a detailed review and data extraction. We reported the number of studies related to each intervention and summarized key cost-effectiveness findings according to intervention type. Costs were converted to 2011 US dollars.


Of the 50 articles that met the inclusion criteria, 33 related to HIV testing, 15 assessed prevention with HIV-positives and partners, three reported on condom distribution, and one reported on policy initiatives. Methodologies and cost-effectiveness metrics varied across studies and interventions, making them difficult to compare.


Our review provides an updated summary of the published evidence of cost effectiveness of four key HIV prevention interventions recommended by CDC. With the exception of testing-related interventions, including partner services, where economic evaluations suggest that testing often can be cost effective, more cost-effectiveness research is needed to help guide the most efficient use of HIV prevention funds.


Policy Initiative Condom Distribution Partner Service Broad Search Strategy Funding Announcement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We sincerely thank Christy Cechman and Barbara Landreth for their help on our literature search. We also thank Paul Farnham, Ram Shrestha, Feng Lin, Chaitra Gopalappa, Robert Koppenhaver, Stephen Sorenson, Steve Nesheim, and Allan Taylor for their help in reviewing and abstracting studies.

Funding and conflict of interest

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. No sources of funding were used to conduct this study or to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author contributions

Conception and design: YLH, AL, SLS; data collection: YLH, AL; analysis and interpretation: YLH, AL, AH, SLS; writing the article: YLH; critical revision of the article: AL, AH, SLS; overall responsibility: YLH.

Supplementary material

40258_2014_142_MOESM1_ESM.docx (151 kb)
Supplementary material 1 (DOCX 150 kb)


  1. 1.
    Farnham PG, Holtgrave DR, Sansom SL, Hall HI. Medical costs averted by HIV prevention efforts in the United States, 1991–2006. J Acquir Immune Defic Syndr. 2010;54(5):565–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520–9.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PloS One. 2011;6(8):e17502.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Hall HI, Green TA, Wolitski RJ, Holtgrave DR, Rhodes P, Lehman JS, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMedGoogle Scholar
  5. 5.
    National HIV/AIDS Strategy for the United States. Office of National AIDS Policy; 2010.Google Scholar
  6. 6.
    CDC. Funding Opportunity Announcement (FOA) PS12-1201: Comprehensive HIV Prevention Programs for Health Departments [cited 8/15/2012]. Available from:
  7. 7.
    CDC. CDC’S New High-Impact Approach to HIV Prevention Funding for Health Departments. Advancing the National HIV/AIDS Strategy [cited 5/11/2012]. Available from:
  8. 8.
    Bureau of Labor Statistics. Medical Care Consumer Price Index [cited]. Available from:
  9. 9.
    Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.Google Scholar
  10. 10.
    Bedimo AL, Pinkerton SD, Cohen DA, Gray B, Farley TA. Condom distribution: a cost-utility analysis. Int J STD AIDS. 2002;13(6):384–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen DA, Wu SY, Farley TA. Structural interventions to prevent HIV/sexually transmitted disease: are they cost-effective for women in the southern United States? Sex Transm Dis. 2006;33(7 Suppl):S46–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009;23(13):1792–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Hutchinson AB, Patel P, Sansom SL, Farnham PG, Sullivan TJ, Bennett B, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7(9):e1000342.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making. 2012;32(3):459–69.CrossRefPubMedGoogle Scholar
  15. 15.
    Long EF. HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PloS One. 2011;6(11):16.CrossRefGoogle Scholar
  16. 16.
    Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011;25(14):1779–87.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102(4):782–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22(14):1829–39.CrossRefPubMedGoogle Scholar
  19. 19.
    Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr. 2011;58(2):e51–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial. International AIDS Conference. Washington DC, US; 2012.Google Scholar
  23. 23.
    Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS One. 2012;7(2):e30216.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Silva A, Glick NR, Lyss SB, Hutchinson AB, Gift TL, Pealer LN, et al. Implementing an HIV and sexually transmitted disease screening program in an emergency department. Ann Emerg Med. 2007;49(5):564–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Lurie P, Avins AL, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272(23):1832–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156(4):394–404.CrossRefPubMedGoogle Scholar
  27. 27.
    Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14(14):2159–69.CrossRefPubMedGoogle Scholar
  28. 28.
    Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Sax PE, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118(3):292–300.CrossRefPubMedGoogle Scholar
  29. 29.
    Walensky RP, Losina E, Malatesta L, Barton GE, O’Connor CA, Skolnik PR, et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005;95(1):71–3.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.CrossRefPubMedGoogle Scholar
  31. 31.
    Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.CrossRefPubMedGoogle Scholar
  32. 32.
    Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806.CrossRefPubMedGoogle Scholar
  33. 33.
    Holtgrave DR. Costs and consequences of the US Centers for Disease Control and Prevention’s recommendations for opt-out HIV testing. PLoS Med. 2007;4(6):e194.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Brown J, Shesser R, Simon G, Bahn M, Czarnogorski M, Kuo I, et al. Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention Guidelines: results from a high-prevalence area. J Acquir Immune Defic Syndr. 2007;46(4):395–401.CrossRefPubMedGoogle Scholar
  35. 35.
    Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123(Suppl 3):51–62.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889–903.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778–89.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Torres GW, Heffelfinger JD, Pollack HA, Barrera SG, Rothman RE. HIV screening programs in US emergency departments: a cross-site comparison of structure, process, and outcomes. Ann Emerg Med. 2011;58(1 Suppl 1):S104–13.CrossRefPubMedGoogle Scholar
  40. 40.
    Hsieh YH, Jung JJ, Shahan JB, Pollack HA, Hairston HS, Moring-Parris D, et al. Outcomes and cost analysis of 3 operational models for rapid HIV testing services in an academic inner-city emergency department. Ann Emerg Med. 2011;58(1 Suppl 1):S133–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Hutchinson AB, Farnham PG, Lyss SB, White DA, Sansom SL, Branson BM. Emergency department HIV screening with rapid tests: a cost comparison of alternative models. AIDS Educ Prev. 2011;23(3 Suppl):58–69.CrossRefPubMedGoogle Scholar
  42. 42.
    Prabhu VS, Farnham PG, Hutchinson AB, Soorapanth S, Heffelfinger JD, Golden MR, et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One. 2011;6(5):e19936.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, et al. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS One. 2011;6(10):12.CrossRefGoogle Scholar
  44. 44.
    Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123(Suppl 3):94–100.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, St Lawrence JS, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Varghese B, Peterman TA. Cost-effectiveness of HIV counseling and testing in US prisons. J Urban Health. 2001;78(2):304–12.CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Shrestha RK, Sansom SL, Richardson-Moore A, French PT, Scalco B, Lalota M, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states—advancing HIV Prevention Demonstration Project, 2003–2006. Sex Transm Dis. 2009;36(2 Suppl):S5–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Shrestha RK, Sansom SL, Schulden JD, Song B, Smith LC, Ramirez R, et al. Costs and effectiveness of finding new HIV diagnoses by using rapid testing in transgender communities. AIDS Educ Prev. 2011;23(3 Suppl):49–57.CrossRefPubMedGoogle Scholar
  49. 49.
    Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2012;6:6.Google Scholar
  50. 50.
    Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One. 2012;7(9):18.CrossRefGoogle Scholar
  51. 51.
    Grobman WA, Garcia PM. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol. 1999;181(5 Pt 1):1062–71.CrossRefPubMedGoogle Scholar
  52. 52.
    Immergluck LC, Cull WL, Schwartz A, Elstein AS. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics. 2000;105(4):E54.CrossRefPubMedGoogle Scholar
  53. 53.
    Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr. 2000;25(5):403–16.CrossRefPubMedGoogle Scholar
  54. 54.
    Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005;38(2):163–73.CrossRefPubMedGoogle Scholar
  55. 55.
    Myers ER, Thompson JW, Simpson K. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998;91(2):174–81.CrossRefPubMedGoogle Scholar
  56. 56.
    Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.CrossRefPubMedGoogle Scholar
  57. 57.
    Lee MB, Leibowitz A, Rotheram-Borus MJ. Cost-effectiveness of a behavioral intervention for seropositive youth. AIDS Educ Prev. 2005;17(2):105–18.CrossRefPubMedGoogle Scholar
  58. 58.
    Marseille E, Shade SB, Myers J, Morin S. The cost-effectiveness of HIV prevention interventions for HIV-infected patients seen in clinical settings. J Acquir Immune Defic Syndr. 2011;56(3):e87–94.CrossRefPubMedGoogle Scholar
  59. 59.
    Rutherford GW, Woo JM, Neal DP, Rauch KJ, Geoghegan C, McKinney KC, et al. Partner notification and the control of human immunodeficiency virus infection. Two years of experience in San Francisco. Sex Transm Dis. 1991;18(2):107–10.CrossRefPubMedGoogle Scholar
  60. 60.
    Pavia AT, Benyo M, Niler L, Risk I. Partner notification for control of HIV: results after 2 years of a statewide program in Utah. Am J Public Health. 1993;83(10):1418–24.CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Spencer NE, Hoffman RE, Raevsky CA, Wolf FC, Vernon TM. Partner notification for human immunodeficiency virus infection in Colorado: results across index case groups and costs. Int J STD AIDS. 1993;4(1):26–32.PubMedGoogle Scholar
  62. 62.
    Toomey KE, Peterman TA, Dicker LW, Zaidi AA, Wroten JE, Carolina J. Human immunodeficiency virus partner notification. Cost and effectiveness data from an attempted randomized controlled trial. Sex Transm Dis. 1998;25(6):310–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13(13):1745–51.CrossRefPubMedGoogle Scholar
  64. 64.
    Ahrens K, Kent CK, Kohn RP, Nieri G, Reynolds A, Philip S, et al. HIV partner notification outcomes for HIV-infected patients by duration of infection, San Francisco, 2004–2006. J Acquir Immune Defic Syndr. 2007;46(4):479–84.CrossRefPubMedGoogle Scholar
  65. 65.
    Shrestha RK, Begley EB, Hutchinson AB, Sansom SL, Song B, Voorhees K, et al. Costs and effectiveness of partner counseling and referral services with rapid testing for HIV in Colorado and Louisiana, United States. Sex Transm Dis. 2009;36(10):637–41.CrossRefPubMedGoogle Scholar
  66. 66.
    Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, Maldonado W, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457–64.CrossRefPubMedGoogle Scholar
  67. 67.
    Halpern MT, Read JS, Ganoczy DA, Harris DR. Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS. 2000;14(6):691–700.CrossRefPubMedGoogle Scholar
  68. 68.
    Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS. 2000;14(16):2543–52.CrossRefPubMedGoogle Scholar
  69. 69.
    Holtgrave DR, Wolitski RJ, Pals SL, Aidala A, Kidder DP, Vos D, et al. Cost-utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV. AIDS Behav. 2012;16:16.Google Scholar
  70. 70.
    Holtgrave DR, Maulsby C, Kharfen M, Jia Y, Wu C, Opoku J, et al. Cost-utility analysis of a female condom promotion program in Washington,DC. AIDS Behav. 2012;16(5):1115–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2014

Authors and Affiliations

  • Ya-Lin A. Huang
    • 1
    Email author
  • Arielle Lasry
    • 1
  • Angela B. Hutchinson
    • 1
  • Stephanie L. Sansom
    • 1
  1. 1.Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB PreventionCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations